Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Prostatic Neoplasms 51Lung Neoplasms 40Carcinoma, Non-Small-Cell Lung 28Neoplasm Metastasis 25Brain Neoplasms 23Lymphoma, Large B-Cell, Diffuse 22Pancreatic Neoplasms 21Breast Neoplasms 20Glioma 19Squamous Cell Carcinoma of Head and Neck 18Glioblastoma 17Multiple Myeloma 16Urinary Bladder Neoplasms 13Colorectal Neoplasms 13Carcinoma, Renal Cell 13Mouth Neoplasms 12Oropharyngeal Neoplasms 11Lymphoma, Mantle-Cell 11Carcinoma 11Triple Negative Breast Neoplasms 10Melanoma 10Leukemia, Lymphocytic, Chronic, B-Cell 10Laryngeal Neoplasms 10Ovarian Neoplasms 9Nasopharyngeal Carcinoma 8Lymphoma, Follicular 8Leukemia, Myeloid, Acute 8Hypopharyngeal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, B-Cell 7

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Metastatic Digestive System Neuroendocrine Tumor G1 × Magnetic Resonance Spectroscopy × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡